Abstract
Utilization of orbital decompressions (ODS) increased (CAGR: +3.2%) from 2000 to 2019. FDA approved teprotumumab in January 2020; ODS utilization decreased (CAGR: -14.9%) from 2019 to 2022. In 2022, total spending was substantially higher for teprotumumab ($325million) than surgery ($580,000).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have